casemark/modeling-organic-vs-inorganic-growth

Modeling Organic Vs Inorganic Growth

Compares build vs. buy alternatives with risk-adjusted returns, time-to-value, and execution probability assessment for capital allocation decisions.

When To Use

• Evaluating whether to build a capability internally or acquire it via M&A
• Comparing capital deployment options across organic R&D, partnerships, and acquisitions
• Assessing strategic alternatives for board or investment committee presentations
• Testing the sensitivity of a make-vs-buy decision to key assumptions (integration risk, time-to-revenue, market timing)

Inputs To Gather

• Organic path: Estimated build cost (capex + opex), hiring plan, development timeline, expected ramp curve to steady-state revenue, probability of technical/market success
• Inorganic path: Target valuation range (EV/Revenue, EV/EBITDA comps), expected synergies (revenue and cost), integration cost and timeline, deal structure (cash/stock/earnout mix)
• Shared baseline: Current revenue and margin profile, cost of capital (WACC or hurdle rate), tax rate, terminal growth assumption, planning horizon (typically 5–7 years)
• Risk parameters: Execution probability for each path, integration failure rate benchmarks for the sector [VERIFY against industry data], competitive response assumptions

Workflow

1. Frame the decision — Define the specific capability or market being targeted. Clarify whether the comparison is binary (build vs. one target) or multi-option (build vs. multiple acquisition candidates vs. partnership).

2. Model the organic path

   • Build a bottoms-up cost model: headcount, infrastructure, marketing spend to launch
   • Project a revenue ramp curve with explicit assumptions on time-to-first-revenue, penetration rate, and steady-state share
   • Apply a probability-of-success discount (e.g., 40–70% for new product lines depending on adjacency) [VERIFY probability assumptions against company track record]
   • Calculate NPV of risk-adjusted free cash flows

3. Model the inorganic path

   • Start with acquisition cost: purchase price, transaction fees (typically 2–5% of deal value), financing costs
   • Layer in integration costs: systems migration, redundancy/severance, customer attrition during transition (commonly 5–15% for B2B) [VERIFY attrition assumptions]
   • Project synergy realization timeline — cost synergies typically 12–18 months, revenue synergies 24–36 months
   • Apply an execution-probability haircut to synergies (full synergy realization is rare; use 60–80% of projected synergies as base case)
   • Calculate NPV including all-in acquisition cost as the upfront outflow

4. Build the comparison framework

   • Side-by-side NPV and IRR for each path at base, upside, and downside scenarios
   • Time-to-value comparison: months to breakeven contribution, months to target revenue run-rate
   • Risk-adjusted return: expected value (NPV × probability of success) for each path
   • Strategic optionality value: does one path create options the other forecloses (e.g., acqui-hire talent, platform for bolt-ons)?

5. Run sensitivity and scenario analysis

   • Tornado chart on the top 5 variables: discount rate, synergy realization %, time-to-revenue, purchase price multiple, organic success probability
   • Break-even analysis: at what acquisition premium does organic become preferred? At what organic delay does inorganic win?
   • Monte Carlo simulation if input distributions are available

6. Synthesize the recommendation

   • Summarize which path delivers higher risk-adjusted value and under what conditions
   • Identify the key swing variables that could change the conclusion
   • Flag any non-financial considerations: cultural fit, regulatory approval risk [VERIFY antitrust thresholds], talent retention, speed-to-market in a competitive window

Output

Deliver a structured comparison memo containing:

• Executive summary — One-paragraph recommendation with the primary rationale and the margin of difference
• Assumptions table — All key inputs for both paths, sourced and flagged where estimated
• Financial comparison — Side-by-side NPV, IRR, payback period, and risk-adjusted expected value
• Time-to-value chart — Visual showing cumulative cash flow or revenue contribution over the planning horizon for each path
• Sensitivity summary — Tornado chart and break-even thresholds for critical variables
• Risk register — Top 3–5 risks per path with likelihood and impact ratings
• Recommendation and conditions — Preferred path with explicit conditions under which the recommendation would reverse

Quality Checks

• NPV calculations use consistent discount rates across both paths (or justify differing rates, e.g., higher WACC for riskier organic build)
• Synergy projections are benchmarked against comparable transactions, not management aspirations alone
• Time-to-value estimates account for realistic ramp periods — not hockey-stick assumptions
• Integration costs are not understated; verify against post-mortem data from prior deals if available
• Probability-of-success discounts are applied to both paths, not just one
• The model does not double-count synergies (e.g., counting revenue synergies in both the target's standalone projection and the combined entity)
• Terminal value does not dominate total NPV (if >60% of value is in terminal, stress-test terminal assumptions separately)
• All [VERIFY] items are resolved or explicitly flagged for decision-maker review before finalizing